Investigating blood cancer risks in patients with ovarian and other solid tumors
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
This study is trying to see if certain cancer treatments for ovarian and other solid tumors can increase the risk of blood cancers in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | University of Washington Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT06295965 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between clonal hematopoiesis and the emergence of therapy-related myeloid neoplasms in patients diagnosed with ovarian or other solid tumors. Participants will provide blood samples and complete surveys, while their medical records will be reviewed to identify potential risk factors and genetic or environmental influences on the development of blood cancers. The study focuses on patients who have undergone specific cancer treatments, particularly platinum-based chemotherapy or PARP inhibitors.
Who should consider this trial
Good fit: Ideal candidates include individuals with a history of ovarian, peritoneal, or fallopian tube carcinoma who have undergone significant chemotherapy or have been treated with PARP inhibitors.
Not a fit: Patients with a life expectancy of less than 6 months or those without a relevant cancer history may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify risk factors for blood cancers in patients with solid tumors, leading to improved monitoring and preventive strategies.
How similar studies have performed: While the investigation of clonal hematopoiesis in cancer patients is an emerging field, similar studies have shown promise in identifying risk factors for blood cancers, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and: * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy OR * Subjects who have or have had a solid tumor diagnosis and any of the following: * At least 4 months of exposure to a PARP inhibitor * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm Exclusion Criteria: * Individuals with a life expectancy of less than 6 months
Where this trial is running
Seattle, Washington
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Elizabeth Swisher — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Swisher Lab Research Coordinators
- Email: swisherlabrc@uw.edu
- Phone: 206-616-8927
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.